Teva Pharma (TEVA) Gets a Buy Rating from Mizuho Securities


In a report released today, Irina Rivkind Koffler from Mizuho Securities reiterated a Buy rating on Teva Pharma (NYSE: TEVA), with a price target of $28. The company’s shares opened today at $22.72.

According to TipRanks.com, Koffler is a 5-star analyst with an average return of 11.5% and a 47.6% success rate. Koffler covers the Healthcare sector, focusing on stocks such as Bausch Health Companies Inc, Eagle Pharmaceuticals Inc, and Pacira Pharmaceuticals.

Currently, the analyst consensus on Teva Pharma is a Hold with an average price target of $23.11.

See today’s analyst top recommended stocks >>

The company has a one-year high of $25.14 and a one-year low of $10.85. Currently, Teva Pharma has an average volume of 10.25M.

Based on the recent corporate insider activity of 26 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Teva Pharmaceutical Industries Ltd. is a global pharmaceutical company, which engages in development, production and marketing of drugs, generic drugs, over-the-counter drugs, active ingredients for the pharmaceutical industry (APIs) and therapeutic products. It operates through two segments: Generic Medicines and Specialty Medicines.

Read More on TEVA:

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts